Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Status:
Not yet recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll
participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO
criteria) targeting the mTOR pathway. Eligible participants will be administered a single
infusion of temsirolimus through super-selective intra-arterial infusion or intravenous
infusion. Participants will receive the study drug administration on the same day as the
planned surgical resection of the tumor.
Phase:
Early Phase 1
Details
Lead Sponsor:
Nader Sanai
Collaborators:
Barrow Neurological Institute Ivy Brain Tumor Center